Luye Pharma schedules board meeting to review interim results, weigh dividendPUBT·Aug 17 at 09:00 AM02186+0.70%
Luye Pharma Group (LYPHF) Receives a Buy from Essence SecuritiesTip Ranks·Jul 24 at 12:05 AM02186+0.70%
Luye Pharma’s Novel CNS Drug LY03015 Delivers Strong Phase 2 Data in Tardive DyskinesiaTip Ranks·Jun 16 at 09:41 AM02186+0.70%
Luye Pharma Raises US$180 Million via Premium-Priced 2031 Convertible BondsTip Ranks·Jun 10 at 07:07 PM02186+0.70%
LUYE PHARMA Issues USD180M CBs at 24.9% Premium, Plans Concurrent Repurchase of 2028 CBsAASTOCKS News·Jun 3 at 08:25 PM02186+0.70%
